Urology Doctors in Berkeley Heights, NJ Accepting Medicare

6 Urology doctors found. Showing 1 - 6

Dr. Adeep Thumar, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8679

Michael Lipsky, Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8679    Fax: 908-277-8909

Dr. Jeffrey Ross Blitstein, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8679

Michael A Volpe, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Summit Medical Group, Berkeley Heights, NJ 07922 Phone: 908-273-4300    Fax: 908-277-8909

Joseph S Ritter, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1 Diamond Hill Rd, Summit Medical Group, Berkeley Heights, NJ 07922 Phone: 908-273-4300    Fax: 908-277-8909

John D Siegal, MD Urology Medicare: Medicare Enrolled Practice Location: 1 Diamond Hill Rd, Summit Medical Group, Berkeley Heights, NJ 07922 Phone: 908-273-4300    Fax: 908-790-6524

News Archive

Children can reliably self-report outcomes of experimental therapy in clinical trials, study suggests

Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life - even at the earliest stages of drug development - making self-reported patient outcomes a potential new clinical trial endpoint, according to a longitudinal validity study led by Children's National Health System researchers.

HDS signs LOI with PharmaLife to market Clotamin in Russia

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC are pleased to announce that HDS has signed a Letter of Intent with PharmaLife for placement of Clotamin with leading pharmacies in the Russian Federation.

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

Each year, the American Thyroid Association (ATA) recognizes the outstanding research contributions of one of its members to a greater understanding of thyroid physiology or the pathophysiology of thyroid disease, with its presentation of the John B. Stanbury Pathophysiology Medal at its Annual Meeting.

Read more Medical News

› Verified 6 days ago